Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses [see Warnings and Precautions (5.1)].CONTRAINDICATIONSXEOMIN is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

  • The potency units of XEOMIN are not interchangeable with other preparations of botulinum toxin products. Therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products.

  • Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted.

  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowi
    '/>"/>

  • SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
    2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
    3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
    4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
    5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
    6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
    7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
    (Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
    (Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
    Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
    ... N.Y., Feb. 6, 2012 /PRNewswire-iReach/ -- SalesCongo ... announced today it has named Kenneth R. Kaisen as its ... as a technology industry veteran with over 25 years of ... Vertis Communications, a marketing communications company. He was previously CEO ...
    ... (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, ... presentation on the Company at the UBS 22nd Annual Global ... EST at the Grand Hyatt New York, New York City. ... Cambrex website http://www.cambrex.com in the Investors section of ...
    Cached Medicine Technology:SalesCongo Names Ken Kaisen CEO 2
    (Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part of ... people, in 2008 he suffered extreme financial hardship and lost ... carefully studied the difference between people who have sustainable and ... the knowledge he acquired, he was able to use what ... but also grow his clients' personal and financial assets while ...
    (Date:7/30/2014)... WHAT: , Resistance to artemisinin, the main drug ... Asia, among the Plasmodium falciparum ( ... and is likely caused by a genetic mutation ... artemisinin-based combination therapyas opposed to a standard three-day ... cases, according to findings published today in the ...
    (Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
    (Date:7/30/2014)... Pennsylvania (PRWEB) July 30, 2014 Visitors ... have contributed over $8,500 to ensure its protection. Bob ... presents a check to the Delaware Highlands Conservancy for ... program. The small $2-per-stay donations add up fast, as ... of the Upper Delaware River Region. , The Kiesendahl ...
    (Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
    Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
    ... , ... ... ... ...
    ... to physical function but also extend to neurological function, according ... Journals of Gerontology Series A: Biological and Medical Sciences ... collection of ten articles highlighting new findings related to obesity ... of improved medical management of cardiovascular disease is that many ...
    ... procedures annually may improve life expectancy, study finds ... with both mammography and MRI appears to be a ... high risk for breast cancer, U.S. researchers say. , ... at Massachusetts General Hospital in Boston, and colleagues used ...
    ... physician shortages, researchers say, , TUESDAY, Feb. 23 (HealthDay News) -- ... a sharp decline in the average number of hours they work ... 1996, the average work week of doctors remained steady, but between ... work dropped nearly four hours a week -- from 54.9 to ...
    ... ... ... , ... , , , ...
    ... ... ... ... , ...
    Cached Medicine News:Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 2Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 3Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 4Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 5Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 6Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 7Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:Mammogram Plus MRI Cost-Effective in High-Risk Women 2Health News:Doctors Working Less, Earning Less 2Health News:Doctors Working Less, Earning Less 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 2Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 4Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 5Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 2Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 3
    Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
    The pediatric blanket provides full coverage for pediatric patient care. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also red...
    Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
    The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
    Medicine Products: